News & Updates

Child abuse rates appear to have increased during the lockdowns imposed to control COVID-19 transmission, according to a study from the US presented at the 2021 American Academy of Pediatrics National Conference & Exhibition (AAP 2021).

The oral antiviral drug umifenovir, which is used to treat influenza, appears to be beneficial in COVID-19 patients who are asymptomatic or with mild symptoms, with a phase III study showing that the drug is well tolerated and can induce viral clearance within 5 days.

Patients with the coronavirus disease 2019 (COVID-19), even those genetically predisposed to the disease, are not at increased risk of developing atrial fibrillation, and vice versa, a study has found.

A large study conducted in Israel has suggested that the effectiveness of the BNT162b2 vaccine against COVID-19 decreases over time.

Long-term exposure to particulate matter ≤2.5 μm (PM2.5) results in increased admission to hospital for COVID-19, according to a recent study.

A decline in daily physical activity (DPA) among patients with idiopathic pulmonary fibrosis (IPF) over a year is noteworthy and disproportionate to a decline in pulmonary physiology, suggests a recent study, noting that this change in DPA may be used as a prognostic tool to assess disease progression.

The pan-sarbecovirus monoclonal antibody sotrovimab appears to reduce the risk of COVID-19 disease progression in high-risk patients, according to interim results of the phase III COMET-ICE* trial.

In post hoc analyses of the phase III SINUS-24 and SINUS-52 trials, the monoclonal antibody dupilumab continued to render improvements for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), as well as among those with comorbid asthma regardless of asthma characteristics.